New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
08:04 EDTNKTRNektar announces dosing of first subject in Phase 1 study for NKTR-171
Nektar Therapeutics announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain.
News For NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 26, 2014
07:31 EDTNKTRNektar announces MOVENTIG receives positive CHMP opinion in EU
Subscribe for More Information
September 24, 2014
10:35 EDTNKTRHigh option volume stocks
Subscribe for More Information
September 19, 2014
09:01 EDTNKTRNektar presents preclinical data on kappa opioid receptor
Nektar announced results from preclinical studies characterizing the analgesic profiles of a series of the company's internally-discovered oral, peripherally-acting kappa opioid receptor agonist molecules. The analgesic properties of kappa receptor agonism are well described in the medical literature.1,2 Kappa opioid receptors are expressed in the peripheral nervous system as well as in the central nervous system, and activation of these receptors at both sites has been shown to result in a reduction in pain and inflammation in a wide range of preclinical models. However, the therapeutic use of kappa receptor agonists has been limited because activation of these receptors in the CNS is associated with significant dysphoria and other unwanted side effects.
September 17, 2014
08:50 EDTNKTRNektar Movantik approval positive, says Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use